Senisca Ltd. has been awarded a £571,350 (US$712,000) grant from Innovate UK toward the development of oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF).
Ocean Biomedical Inc. announced it will be targeting its pulmonary fibrosis treatment candidate OCF-203 as a novel therapeutic for fatal pulmonary fibrotic conditions caused by Hermansky-Pudlak syndrome (HPS).
Researchers at Indiana University Bloomington have developed allosteric modulators of the opioid receptor that were superior to the opioid antidote naloxone at blocking the effects of fentanyl in vitro. They presented their work in a session on “Progress towards more efficacious medicine: Antibiotics and antidotes” at the 2023 spring meeting of the American Chemical Society (ACS).
New research has shed light on a molecular mechanism that fuels inflammation in acute lung injury (ALI), a severe and often fatal condition. Macrophage necroptosis, a form of cell death, is a necessary process contributing to intrapulmonary inflammation during ALI. However, the molecular mechanism that initiates macrophage necroptosis has remained unclear until now.
Tetra Bio-Pharma Inc. has received clearance from Health Canada to proceed with a first-in-human trial in Canada using oral ARDS-003 (onternabez) to treat various immunomodulatory conditions. Oral ARDS-003 is positioned to modulate acute systemic inflammation and prevent sepsis, acute respiratory distress syndrome (ARDS) and organ damage.
RSS
